Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) Invests More Than $7 Million in C2N Diagnostics’ Blood Tests
New investment supports DxA's mission to advance the development of scalable and universally accessible diagnostics.Blood tests will be key to...